Mobile Site ›
Print Friendly View

Test ID: AMPCS    
AMPA-Receptor Antibody by CBA, Serum

Secondary ID A test code used for billing and in test definitions created prior to November 2011

61518

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluating new onset encephalopathy encompassing 1 or more of the following: confusional states, psychosis, delirium, memory loss, hallucinations, seizures, dyssomnias

 

The following accompaniments should prompt suspicion for autoimmune encephalopathy:

-Headache

-Autoimmune stigmata (personal or family history, or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)

-History of cancer

-Smoking history (20+ pack years) or other cancer risk factors

-Inflammatory cerebrospinal fluid or isolated protein elevation

-Neuroimaging signs suggesting inflammation

 

Evaluating limbic encephalitis

 

Directing a focused search for cancer

 

Investigating encephalopathy appearing in the course or wake of cancer therapy, and not explainable by metastasis or drug effect

Method Name A short description of the method used to perform the test

Cell-Binding Assay (CBA) Detects IgG Specific for 2 Amino-3 (5-Methyl 3 Oxo-1,2 Oxazole 4 Yl) Propanoic Acid Receptor (AMPA-R) by Indirect Immunofluorescence (IFA)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

AMPA-R Ab CBA, S

Aliases Lists additional common names for a test, as an aid in searching

a-Amino-3-Hydroxyl-5-Methyl-4-Isoxazole-Propionate Receptor Ab
AMPA Receptor Ab
Anti-AMPA